Introduction
It is evident that cancer patients display a wide range of treatment sensitivities with regard to both tumor and normal tissue responses. Predictive biomarkers are urgently needed for individualization of radiation therapy and DNA damaging systemic therapies, which includes chemotherapeutics, therapeutic antibodies, and molecularly targeted drugs such as poly(ADPribose)polymerase (PARP) inhibitors. Following exposure to ionizing radiation (IR) and many drugs, DNA double-strand breaks (DSBs) represent the principal lesion which, if not adequately repaired, can lead to cell death via the generation of lethal chromosomal aberrations or other mechanisms (reviewed in ref. 1 ). Alternatively, an inaccurately repaired or unrepaired DSB may result in mutations or genomic rearrangements in a surviving cell, thereby promoting genomic instability and malignant cell transformation. Complex DNA damage response (DRR) pathways have evolved, and are evolutionarily conserved, to protect the cell from the potentially deleterious effects of a DSB. Two principle pathways, homologous recombination repair (HRR) and non-homologous end-joining (NHEJ), remove DSBs by employing separate as well as overlapping protein complexes.
There is increasing evidence from functional studies and recent genomic analyses that alterations of DNA repair exist in human tumors that may impact treatment sensitivities [2] [3] [4] [5] [6] [7] [8] . Therefore, identification of alterations in the DDR following DSB induction would be very useful for individualization of treatments. Possible treatment modifications include (de-)escalation of radiation dose or combining radiation therapy with targeted drugs that further exploit pre-existing DNA repair defects. It is possible that whole genome sequencing will ultimately provide us with sufficient information on the overall state of DSB repair in a given tumor to inform treatment approaches that produce DSBs . However, it is also possible, and in our opinion more likely, that genomic information will be in most cases insufficient to predict how tumors will respond to therapeutic DSBs (with some exceptions such as predicted synthetic lethality resulting from BRCA mutations and PARP inhibition 9 ).
Willers et al., Functional Biomarkers of the IR Response 4
Many investigators now believe that a functional assessment of the DDR in human tumor tissues can be used to predict treatment sensitivities 2, 4, 5, 8 . Such functional assays most often rely on the detection of subnuclear foci of DDR proteins (reviewed in ref. 10 ). Foci represent multiprotein complexes that are organized into centers surrounding a DSB and can be visualized as "dots" using immunofluorescence microscopy in cells and tissues ( Figure 1A ). These complexes are highly dynamic structures in order to coordinate DNA repair and checkpoint responses. Many DDR proteins shuttle transiently in and out of the focus, or are degraded at the damage site. The composition of these repair centers depends on the type of DNA damage and the cell cycle phase of the damaged cell. The regulation of its components is ensured through complex post-transcriptional modifications and other mechanisms. The accumulation of DDR factors around a DSB is thought to serve multiple purposes including sheltering the broken DNA ends from decay, preventing undesired repair from occurring, and promoting chromatin relaxation to facilitate access of repair proteins. The increased concentration of many DDR proteins around the damage site likely stimulates their activities and results in an amplification of the DNA damage signal. Foci may also serve as a "toolbox" in which DDR proteins assemble to promote different repair pathways 10 .
There exists a vast literature on foci responses in established cell lines and a considerably smaller but emerging body of data on conducting foci assays on tissues and cells from patients 4, 5, 8, [11] [12] [13] [14] .
The focus of the current review is to provide an overview of the opportunities as well as technical challenges associated with the use of patient samples. The reader is also referred to a number of recent reviews on this and related topics 10, [15] [16] [17] [18] [19] . Overall, the analysis of DDR foci in patient-derived samples is feasible and reliable but correlations of foci data with clinical outcomes are urgently needed.
DDR Foci Endpoints: γ γ-H2AX and 53BP1
One of the earliest events in the DDR is the rapid phosphorylation of the histone variant H2AX
at serine 139, four residues from its carboxyl terminus, in the vicinity of the DSB by members of the phosphatidylinositol 3-kinase family, i.e., Ataxia Telangiectasia Mutated (ATM), AT and Rad3-related [27] [28] [29] [30] [31] . Even for the low but clinically relevant dose of 2 Gy the correlation seems to hold although at this dose the assay may only be able to identify the most radiosensitive tumors ( Figure   1B ). With appropriate assay modifications, the clinical value of residual γ-H2AX will also lie in the prediction of radioresistance and in the prediction of radiosensitization caused by a molecular targeted agent. This is illustrated in Figure 1C , D where the addition of a heat shock protein 90 inhibitor clearly increases the number of residual γ-H2AX foci in some head and neck squamous cell carcinoma (HNSCC) cell lines which correlates with the ability of this agent to radiosensitize cells. In fact, a large number of molecularly targeted agents may radiosensitize through modulation of DSB repair as Table 1 illustrates 32-53 . If this were to hold true in tumor biopsies from patients, γ-H2AX could be a very useful biomarker to guide the clinical administration of radiosensitizing targeted drugs.
Gamma-H2AX can be quantified by Western blotting, flow cytometry analysis, or by enumerating discrete foci using microscopy 15 . Although flow cytometry has the advantage of fast and high sample throughput, microscopy is the most sensitive method for γ-H2AX foci detection and, therefore, is the predominant technique of γ-H2AX detection in current pre-clinical applications 19, 54, 55 .
Specifically in patient samples, several additional reasons account for microscopy as the method of choice to detect γ-H2AX foci: i) detection of individual DSB marked by foci, ii) heterogeneous responses in tumor tissue (e.g. oxic or hypoxic regions), iii) discrimination between foci from tumor cells or surrounding normal tissue, and iv) the degree of DNA damage (e.g. pan-staining in apoptotic, mitotic or necrotic cells, diffuse foci in S-phase cells).
The tumor suppressor TP53 binding protein 1 (53BP1) is an alternative marker for visualization of IR-induced DSBs 56 ( Figure 1E , Table 1 ). Accumulating evidence suggests that it is located upstream in the DDR and involved in regulation of both HRR and NHEJ 57, 58 . Potentially, it is more specific for marking DSB than γ-H2AX which also stains areas of DNA not containing a DSB and apoptotic nuclei 59, 60 . However, more comparative studies of γ-H2AX and 53BP1 in human samples are needed 61, 62 .
Lastly, an imaging probe capable of revealing DSB in-vivo could provide useful information regarding treatment response and bypass the technical difficulties surrounding microscopy-based foci analysis on biopsy specimens as is further discussed below. The high abundance of γ-H2AX
expression in tumor cells is most likely sufficient for molecular imaging. Cornelissen et al. 63 developed a radioimmunoconjugate that targets γ-H2AX, 111 In-DTPA-anti-γH2AX-Tat, and is able to penetrate the cell and its nucleus. The radioimmunoconjugate was used to visualize radiation-induced accumulation of γ-H2AX with in-vivo fluorescence imaging and single photon emission computed tomography in a heterotopic breast cancer model. Although the probe warrants further validation such as dose response correlations, in-vivo imaging holds the promise of a non-invasive imaging tool for detecting treatmentinduced DSBs in preclinical and clinical settings.
DDR Foci Endpoints: Focus on HRR
Of the two principal DSB repair pathways, NHEJ and HRR, the latter is more readily assayed owing to the nature of many HRR proteins to form visible foci. Foci of the main HRR recombinase, "proficient" versus "deficient" cell. In addition, FA pathway defects are expected to only affect foci formation in S-phase, so that normal RAD51 foci formation in G2-phase can potentially mask any foci alterations in S-phase in an asynchronous cell population. This highlights the general need to assess cell cycle distributions and cell cycle specificity of RAD51 foci formation when conducting these studies.
BRCA1 and RAD51 co-localize in S-phase foci, consistent with a functional relationship between these two proteins 72 . BRCA1 foci are present in undamaged S-phase cells where they may be involved in processing stalled replication forks due to endogenous DNA damage. Following induction of exogenous DNA damage, these foci disperse and relocate at exogenous damage sites that contain RAD51 73 . The recruitment of BRCA1 into foci is complex and involves several protein complexes with functions that extend beyond HRR control (reviewed in ref. 74 ). Mutations in the BRCA1 gene will disrupt BRCA1 foci formation and impair RAD51 foci formation, while alterations in directly or functionally interacting proteins, such as MDC1, may attenuate the induction of BRCA1 foci in response to DNA damage 75, 76 .
The recruitment of FANCD2 into subnuclear foci is dependent upon mono-ubiquitination by the FA core complex as well as BRCA1 function 69 . To which extent FANCD2 is involved in the promotion of HRR remains poorly defined 77, 78 . One role of FANCD2 in foci may be to facilitate HRR needed for replication fork restart 79, 80 . Thus, attenuated or absent FANCD2 foci are expected to predict sensitivity 17 ). This is likely due to high baseline expression in the nucleus and a requirement for a smaller number of molecules at the DSB site compared to HRR proteins. Phosphorylation of DNA-PKcs is required for NHEJ and can be detected as foci, but whether this can be used as a surrogate for NHEJ proficiency remains unknown 82 .
Requirement for a DNA Damage Signal to Induce Foci
It is obvious that measurement of therapeutic DSBs using γ-H2AX or 53BP1 foci requires preceding exposure to DNA damaging agents. It is also important to appreciate that the activity of the HRR pathway is similarly dependent on the ability to localize these proteins into foci, in order to coordinate and execute repair, but less dependent on protein expression levels 10 the ability to induce RAD51 foci. This functional difference is associated with a pronounced difference in sensitivity to mitomycin C ( Figure 2B ). This illustrates the importance of "functional biomarker" analysis (i.e., RAD51 foci) rather than assessment of "biomarker expression" (RAD51 expression).
Thus, the functional status of HRR (as an example of the DDR in general) is typically revealed only when cells are exposed to DNA damage. It should be possible to use the ability of cells to form DDR foci as a functional biomarker of the integrity of the DDR network, and vice versa interpret the absence of repair foci induction, coupled with a persistence of DSB markers γ-H2AX or/and 53BP1, as an indicator of treatment sensitivity. This is illustrated in Figure 2C .
DDR Foci Assays on Human Samples
Administration of radiation therapy with or without radiosensitizing agents will induce DNA damage not only in the tumor but also in the normal tissues. Although measurement of DDR foci is well established in in-vitro cell cultures, methods to translate these assays into patient-derived samples remain highly experimental. Assessing the foci response in live tumors would require a repeat biopsy following initial administration of treatment. Not only is such an approach limited to cancers that are easily accessible for a needle biopsy, such as head and neck, breast, extremity sarcoma, or cervix cancers, personalization of therapy may be difficult after it has been already initiated. DDR foci can also be assessed in circulating tumor cells (CTCs) or peripheral blood lymphocytes (PBL). The most promising alternative is the use of pre-treatment biopsies. Such samples can be interrogated for their ability to form DDR foci in order to select the appropriate treatment regimen for a given patient. This requires some form of ex-vivo approach to expose tumor tissues or other samples to DNA damage in the laboratory.
Several groups have used ex-vivo assays in recent years to monitor DDR foci responses following treatment with IR or drugs 4, 5, 8, 13, 14, 85 . This approach is based on the idea that tumor tissues can remain viable for several days if cultured properly following removal from the patient. The use of organotypic slice cultures is a method long established in the field of neurological science and only recently expanded to the study of cancers [86] [87] [88] [89] . Vaira et al. 89 established organotypical cultures from a variety of previously untreated epithelial cancers. Slices of 300-500 μm were cut from surgical samples with a vibratome and cultured on organotypical inserts to preserve the three-dimensional (3D) tissue architecture. Cell viability assays, gene expression profiling, and assessment of PI3K/AKT activity validated the ex-vivo culture approach for up to five days following removal from the patient.
Our own approach has been driven by the desire to obtain rapid read outs of treatment sensitivity using needle biopsies that can ultimately inform treatment decisions in real time 13, 90 (Figure 3) . In brief, core biopsy materials are obtained, placed in chilled complete cell culture medium with 10% serum, and equilibrated in a humidified cell culture incubator at 37°C and 5% CO 2 . Within 60-90 minutes after removal from the patient the specimen is divided into smaller samples and subjected to mock treatment, IR with 4-10 Gy, or drug treatments, depending on the amount of tissue available 13 .
Following ex-vivo treatments, samples continue incubation for 5-48 hours depending on the particular experiment to allow for DDR foci formation. In cases where we do not extend incubation beyond ~24
hours we do not add antibiotics or antifungals to the medium. However, this may be considered when the microbial burden in the tumor specimen is high due to tumor location in the mouth or intestine. depending on the particular experiment and presence of intra-tumoral heterogeneity).
Using the above approach, we conducted a pilot study in which core biopsies from seven women with previously untreated, locally advanced breast cancers (without BRCA1/2 mutations) were subjected to 8 Gy irradiation or mock treatment ex-vivo 13 . RAD51, BRCA2, and FANCD2 foci could be readily visualized in individual irradiated cells from three tumors with an intact foci response, while the other four tumors lacked foci induction. Yet, there was no difference in the baseline of foci numbers in non-irradiated tumor cells. Notably, three of the four foci-defective tumors were "triple-negative", a phenotype associated with BRCA1 deficiency. There was reduced BRCA1 expression in only two of the four foci-defective tumors. Even though the number of subjects in this study was small, these data suggested that gene expression may correlate poorly with HRR pathway activity as measured by foci formation, and further, that a functional pathway defect is only revealed upon DNA damage induction,
i.e., ex-vivo treatment.
Simon Powell's group has expanded on this approach and in a preliminary analysis identified six out of 30 breast cancers lacking a RAD51/BRCA1 foci response 85 . Furthermore, instead of using core biopsies, an approach involving fine-needle biopsy aspirates was developed. Breast cancer aspirates were made into a cell suspension in ~1 ml of phosphate buffered saline, ex-vivo irradiated or mock treated, incubated for 4 hours, and fixed on glass slides after processing the cell suspension in a cytospin. It was felt that the staining process was generally easier compared to using intact tumor tissues, with less permeability problems and a better signal-to-noise ratio. The downside of this approach is loss of the 3D tissue architecture.
CTCs can be non-invasively isolated from the patient's blood and are therefore available for Despite major improvements in cancer therapy for many tumor entities the overall cure rates are still unsatisfying and biomarkers for treatment individualization are needed 96 . Soon after the discovery of the crucial functions of γ-H2AX in DSB repair it was hypothesized that the rate of γ-H2AX foci reduction due to repair and the relative residual DNA damage after exposure to IR would be a useful indicator for the intrinsic radiosensitivity of cells. A more rapid foci reduction and less retention were assumed to be associated with a more radioresistant cell type 97 .
The possibility of using γ-H2AX foci as a potential predictor of tumor response to treatment was first explored in cohorts of advanced carcinomas of the uterine cervix 98, 99 . Comparison of residual excision repair and mismatch repair seem to be the major pathways to repair 5-FU-induced DNA damage independent of DSBs 108 . Nonetheless, the γ-H2AX assay seems to have the potential to predict the individual sensitivity to 5-FU-based combination treatments 16 . Interestingly, after ex-vivo irradiation of PBL, the γ-H2AX assay was very precise in terms of predicting radiosensitivity relative to in-vivo irradiated PBL 109 . However, concurrently administered chemotherapeutics, especially cisplatin, limit the precision of this method for predicting radiosensitivity 107, 109 . In contrast, as suggested in Table   1 , γ−H2AX assays will likely be useful to assess combinations with radiosensitizing targeted drugs that do not increase DSB levels unless they are combined with IR.
Identification of HRR Defects for Prediction of Treatment Sensitivity
The identification of HRR-defective tumors is important for several clinical applications such as prediction of radiosensitivity (including potential hypersensitivity to proton beam radiation 110 ), chemosensitivity (in particular platinum drugs), and many targeted agents (e.g., PARP inhibitors). At a minimum, this will involve assaying for key proteins such as γ-H2AX and RAD51 foci, but ideally also additional central DDR regulators such as BRCA1, FANCD2, and others.
Van Gent and colleagues obtained 54 fresh primary breast cancer samples from patients undergoing surgery 5 . Organotypic slice cultures were prepared and subjected to 5 Gy irradiation.
Incubation and irradiation of samples was performed within 6 hours after surgical resection. Two hours after irradiation, samples were fixed in formalin and paraffin embedded. Sections were stained for DAPI, geminin (to identify cells in S/G2-phase), and RAD51. A cell was considered positive for RAD51
foci if more than five nuclear foci were detected. Using this approach, 11% of tumors displayed a RAD51 foci defect. The foci defect was significantly associated with triple-negative breast cancer, and two of five HRR-deficient tumors did not show mutations in the BRCA genes but BRCA1 promoter hypermethylation. The authors suggested that the RAD51 foci ex-vivo assay faithfully identifies HRRdeficient tumors and has clear advantages over gene sequencing. It is a relatively easy assay that can be performed on biopsy material, making it a powerful tool to select patients with an HRR-deficient cancer for PARP inhibitor treatment in the clinic.
The authors noted that the observed ~10% incidence of HRR-defective tumors was lower than prior estimates of ~25% of HRR defects in sporadic breast cancers [11] [12] [13] 111 . However, conducting the assay with IR alone at a relatively short time point (2 hours) is likely to only capture severe HRR defects due to BRCA1/2 disruption but will miss a number of other HRR defects. For example, our own in-vitro data indicate that tumor cells with an S-phase specific HRR defect, for example due to an alteration in the FA pathway, may display normal RAD51 foci induction after IR exposure but defective induction after replication-fork blocking treatments, such as cisplatin 90 . To detect this, a 24-hour time point would be required.
Another study performed the RAD51 foci assay on biopsies from 68 sporadic breast cancers that were obtained 24 hours after the first cycle of anthracycline-based chemotherapy 111 . The authors scored RAD51 and γ-H2AX foci on FFPE tumor tissues. A geminin-positive nucleus was scored as positive if it contained at least at one RAD51 focus. A low RAD51 foci score of < 10% positive nuclei was found in 26% of cancers. In a subset analysis it was shown that low RAD51 foci scores did not reflect lack of drug effect as there was a concomitant high γ-H2AX foci score as a marker of induced DSB. Interestingly, a low RAD51 foci score was seen in 67% of the twelve triple-negative cancers, compared to 19% in the other cancers, and a low RAD51 score was correlated with pathological complete response at the time of surgery. The challenge of conducting an in-vivo approach such as this includes the logistics of obtaining a biopsy during treatment and uncertainties surrounding drug concentration in the biopsied tumor area.
Interestingly, HRR defects seem to be common in a variety of epithelial tumor types with incidences that appear to be in the order of 15-25% in many cases (reviewed in ref. indicating a putative HRR defect and suggesting cisplatin sensitivity. In-vitro analysis, however, indicated that γ-H2AX foci were actually superior to RAD51 foci in terms of predicting cell kill by cisplatin, likely because mechanisms other than loss of RAD51 function can also cause cisplatin sensitivity. In addition, HRR defects can manifest themselves not only as a failure to induce RAD51 foci but also a failure to resolve foci, presumably due to defects in resolvase proteins such as SLX4 or FAN1 90, 110 . Detection of this phenomenon would require more than one time point and extending tissue incubation to at least 48 hours, which may be difficult to carry out on limited amounts of biopsy materials. Thus, foci scores or signatures encompassing at least several DDR proteins will have to be designed to accurately assess the DDR after treatment at an early time point.
These data also indicate that anti-cancer drugs will penetrate tumor tissue samples ex-vivo and elicit a DDR as illustrated in Figure 1A and 4A. With this type of assay one can envision a rapid assessment of drug sensitivities on biopsy material ex-vivo and results reporting within a few days. This is of particular interest for current efforts to identify predictive biomarkers of PARP inhibitors which can be employed in monotherapy or in combination therapy, for example with IR. While some data suggest that IR-based ex-vivo assays will accurately predict PARP inhibitor sensitivity 5,112 , we are not aware of any studies that have exposed organotypic 3D cultures to PARP inhibitors. To this end, Curtin and colleagues established cell cultures from malignant pleural effusions obtained from 13 patients with various cancers 8 . Cultures were exposed to a PARP inhibitor, and RAD51 and γ-H2AX foci were scored, in parallel to next-generation sequencing of DNA repair genes. The authors determined that one third of cultures had a HRR defect. No mutations in DNA repair genes were associated with HRR status in this small cohort. Intra-and inter-tumoral heterogeneity of foci formation within tumor specimens is of considerable concern. This is already well established for γ-H2AX foci where it may relate to genomic instability and other factors 99 . Figure 1F shows immunohistochemistry images of a HNSCC sample stained for tumor cell identification (panel a) and assessment of oxygenation status (using pimonidazole) and cell viability (BrdU) (panel b). This type of co-staining is important because hypoxia can affect γ-H2AX foci formation as well as other DSB repair pathways 113, 114 . In this context, it is unknown how potential changes in hypoxia/reoxygenation upon removal of the tumor tissue from the patient and incubation in the laboratory at ~20% oxygen will affect foci readouts. Studies to compare invivo irradiated tumors with ex-vivo irradiated biopsies are currently being conducted in Dresden to determine the possible influence of ex-vivo culturing on foci formation. Similarly, foci of HRR proteins may vary considerable as they will only occur in cells that are in S-or/and G2-phase. The fraction of cells in these cell cycle phases is much lower in tissues than in established cell lines in-vitro. In addition, there can be considerable heterogeneity with regard to the presence of cycling tumor cells within a biopsy specimen. This is illustrated in Figure 4B which shows the quantification of RAD51 foci responses following ex-vivo treatment of lung cancer samples with cisplatin. In some tumors there is considerable variation of RAD51 foci counts across different parts of the sample, and in untreated tumors this variation could mask any treatment-induced foci increase. In another example, FANCD2 foci induction by IR is predicted to be S-phase specific and thus can be clearly heterogeneous ( Figure 1G ). These problems may be overcome by simply increasing the number of analyzed images or/and co-staining with S/G2 markers such as geminin or PCNA.
Technical Challenges of Foci Studies in Tumor Tissues
Occasionally it is difficult to identify tumor cells based on DAPI morphology alone, which requires additional stains such as cytokeratin or H&E. Foci counting is labor-intensive, indicating a need for automation of foci scoring. Appropriate software applications are available for foci analysis in cell cultures but sophisticated solutions to semi-quantify foci in tumor specimens are missing 8, 120 . However, we find that manual scoring by a trained investigator or technician is more reliable in terms of distinguishing foci from unspecific stains or artifacts, which in a tissue context are quite common. To this end, it must be emphasized that staining of tumor tissue for DDR foci requires extensive optimization especially when co-staining is involved, and antibody performance can differ quite dramatically from in-vitro experiments. Nonetheless, solid tumor specimens with preserved 3D
architecture have a major advantage: they are the closest model of the actual tumor and should therefore predict the clinical treatment outcome most precisely.
γ γ-H2AX Assays for Biodosimetry and Prediction of Normal Tissue Toxicity
While the focus of this review is on foci assays in tumor tissues we will also briefly address data on the value of γ-H2AX for the measurement of IR exposure and prediction of normal tissue toxicity.
Particularly the excellent correlation of γ-H2AX foci and IR exposure doses in lymphocytes support the promise of using γ-H2AX in tumors 19 , assuming that intra-and inter-tumoral heterogeneity with regard to foci expression can be overcome.
Isolation of PBL from patient blood samples is a non-invasive method which guarantees easy access of biomaterial and repeated measures during treatment. These liquid biopsies are widely used in biodosimetry to estimate the delivered dose to an exposed individual 121 . For example, the analysis of The γ-H2AX foci assay also has been used on ex-vivo irradiated blood lymphocytes as a clinical biomarker to identify small subsets of patients at risk of severe normal tissue toxicity. Microscopic foci analysis was confirmed as the method of choice by comparing three different methods (foci, comet, and neutral filtration assay) to detect a γ-H2AX signal in ex-vivo irradiated (2 Gy) PBLs from 54 HNSCC patients receiving radiation/chemotherapy. The foci assay could best detect a correlation of γ-H2AX
signal and acute oral mucositis and dermatitis (grade ≥3) 123 . In two studies with 41 and 47 pediatric solid tumors and leukemia patients receiving DNA-damaging therapy, γ-H2AX foci were evaluated in ex-vivo irradiated PBL which enabled the identification of patients at risk for high-grade acute and late toxicities and allowed for detection of DSB repair deficiencies, although not all treatment-associated normal-tissue toxicities could be explained by DSB repair insufficiencies 124, 125 . Similar observations were made with regard to severe late effects in prostate cancer patients and acute (grade ≥2) dermatitis in breast cancer patients 106, 126 . In contrast to these findings, a number of studies which also used blood lymphocytes for γ-H2AX evaluation could not find a correlation with acute side effects 109, 127, 128 . However, caution must be taken with the interpretation of these results. None of the above studies was randomized, all were performed at single institutes, and the recruited patient numbers are generally low.
Conclusions
Over the next few years, genomic profiling of human cancers will provide us with unprecedented insight into the mutational landscape of genes directly or indirectly involved in the DDR. However, to what extent this wealth of structural information about the cancer genome will reveal biomarkers of radiosensitivity and radiosensitization by anti-cancer agents remains to be seen. The concept of highly ordered and regulated protein machineries at the DSB has profound implications for the development of biomarkers to predict the functional status of DSB repair in a given cancer. Even if the entire genome and epigenome of a cancer was deciphered, a lack of in-depth knowledge of the functional interactions of DDR gene products and other regulatory components would complicate predictions of DSB repair proficiency and cellular sensitivity to anti-cancer agents including IR. These considerations stress the value of functional DDR assays that can provide a measure of DSB repair without needing to fully understand the functional consequences of all genomic alterations.
The advantage of using DDR foci as functional biomarkers is that they can detect repair defects due to several mechanisms such as gene mutations, epigenetic events, or alterations in signal transduction pathways which are increasingly recognized as modulating DDR 10 . Moreover, they hours after exposure of lung cancer tissues to cisplatin (8 μM). Data points represent foci counts from random high-power images 4 . Figure 1 
